In our recent paper [(1)][1], we demonstrated that both B-type natriuretic peptide (BNP) and N-terminal pro-BNP at baseline and during treatment with angiotensin receptor-neprilysin inhibitor (ARNI) were found to be… Click to show full abstract
In our recent paper [(1)][1], we demonstrated that both B-type natriuretic peptide (BNP) and N-terminal pro-BNP at baseline and during treatment with angiotensin receptor-neprilysin inhibitor (ARNI) were found to be independently and comparably associated with cardiovascular risk based on data from
               
Click one of the above tabs to view related content.